Syntimmune Inc.

Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue

Plus Spear resigns at Poseida and updates from Cambridge Enterprise and Gaba

Arch Oncology, the latest CD47-focused biotech to draw big money with its $105 million series C round, plans to use its new capital to broaden the clinical development program for AO-176 and add new

SVB Leerink hired Andrew Fineberg as managing director to lead the firm’s new structured finance group. Fineberg joins from MTS Health Partners, where he served as partner and head of royalty

Samsung Biologics promoted EVP John Rim to president and CEO. Before joining the South Korean company in 2018, Rim worked for Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for 14 years in

A rare Alexion deal for a marketed product comes at a relative discount as Portola’s stock price has sunk

Clinical data in myasthenia gravis starts to separate which mechanisms do and don’t work